Search research articles
Contact Us
Filters
Showing results (61-70 of 269) with videos related to
Page
of 27
Sort By:
Thrombosis and Haemostasis
|
June 16, 1988
Spuriously low levels of protein C with a Protac activation clotting assay
P de Moerloose, G Reber, C A Bouvier
Journal of Pharmaceutical and Biomedical Analysis
|
January 1, 1985
Fluorimetric analysis of mebendazole and flubendazole with hydrogen peroxide
W Baeyens, F A Fattah, P De Moerloose
Seminars in Vascular Medicine
|
June 17, 2004
Venous thromboembolic disease: risk factors and laboratory investigation
M Alhenc-Gelas, M Aiach, P de Moerloose
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
July 14, 2016
Rare coagulation disorders: fibrinogen, factor VII and factor XIII
P de Moerloose, J-F Schved, D Nugent
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|
July 1, 1996
Optimal duration of oral anticoagulant therapy following deep vein thrombosis of lower limbs
H Bounameaux, P de Moerloose, F P Sarasin
Lupus
|
March 13, 2003
Severe thrombocytopenic purpura due to rubella infection in a patient with systemic lupus erythematosus
F Boehlen, J F Balavoine, P de Moerloose
Revue Medicale Suisse
|
March 21, 2007
[Inherited thrombophilia and arterial diseases]
H Robert-Ebadi, F Boehlen, P de Moerloose
Journal of Thrombosis and Haemostasis : JTH
|
January 20, 2016
Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study
T Marchetti, P de Moerloose, J C Gris
Clinical and Experimental Rheumatology
|
November 1, 1990
Anticardiolipin antibody determination: comparison of three ELISA assays
P De Moerloose, G Reber, J J Vogel
Die Pharmazie
|
October 1, 1986
Chromatographic isolation and mass spectrometric identification of a base-induced mebendazole fluorophor
W Baeyens, F Abdel Fattah, P De Moerloose
Page
of 27
Search research articles
Search
Showing results (61-70 of 269) with videos related to
Sort By:
Page
of 27
Thrombosis and Haemostasis
|
June 16, 1988
Spuriously low levels of protein C with a Protac activation clotting assay
P de Moerloose, G Reber, C A Bouvier
Journal of Pharmaceutical and Biomedical Analysis
|
January 1, 1985
Fluorimetric analysis of mebendazole and flubendazole with hydrogen peroxide
W Baeyens, F A Fattah, P De Moerloose
Seminars in Vascular Medicine
|
June 17, 2004
Venous thromboembolic disease: risk factors and laboratory investigation
M Alhenc-Gelas, M Aiach, P de Moerloose
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
July 14, 2016
Rare coagulation disorders: fibrinogen, factor VII and factor XIII
P de Moerloose, J-F Schved, D Nugent
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|
July 1, 1996
Optimal duration of oral anticoagulant therapy following deep vein thrombosis of lower limbs
H Bounameaux, P de Moerloose, F P Sarasin
Lupus
|
March 13, 2003
Severe thrombocytopenic purpura due to rubella infection in a patient with systemic lupus erythematosus
F Boehlen, J F Balavoine, P de Moerloose
Revue Medicale Suisse
|
March 21, 2007
[Inherited thrombophilia and arterial diseases]
H Robert-Ebadi, F Boehlen, P de Moerloose
Journal of Thrombosis and Haemostasis : JTH
|
January 20, 2016
Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study
T Marchetti, P de Moerloose, J C Gris
Clinical and Experimental Rheumatology
|
November 1, 1990
Anticardiolipin antibody determination: comparison of three ELISA assays
P De Moerloose, G Reber, J J Vogel
Die Pharmazie
|
October 1, 1986
Chromatographic isolation and mass spectrometric identification of a base-induced mebendazole fluorophor
W Baeyens, F Abdel Fattah, P De Moerloose
Page
of 27